![BioMark Diagnostics Inc.]

165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK PARTNERS WITH ALBERTA MACHINE INTELLIGENCE INSTITUTE TO AMPLIFY CLINICAL DIAGNOSTIC DECISION MAKING

Vancouver, British Columbia – (April 25, 2018) – BioMark Diagnostics Inc. ("BioMark") (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to announce that it has penned a deal with the Alberta Machine Intelligence Institute (Amii) led by Dr. Osmar Zaïane of the University of Alberta's Department of Computing Science and his team to assess and employ machine intelligence to augment BioMark's breakthrough biological molecular diagnostics for lung cancer that leverages the power of metabolomics.

BioMark, over the past few months, has been actively working with the team at Amii to find optimal methodologies to increase the prediction and accuracy of its assays. President and CEO Rashid Bux says, "We realize the importance of machine and deep learning in the future of healthcare delivery. There is immense impact in patient care outcome and faster diagnostic utility for clinicians through incorporating machine intelligence capabilities. Our initial objective is to increase the performance and prediction of our lung cancer diagnostic assays by reducing data bias to establish consistency. Eventually, we aim to establish models that have the ability to predict trends in our network, which will amplify decision making for clinicians. Once completed, BioMark intends to incorporate this as an application-driven breakthrough embedded seamlessly onto our technology platform. BioMark is delighted to work with Dr. Zaïane and Amii from University of Alberta who are creating game changing applications using machine learning and artificial intelligence."

About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

About Alberta Machine Intelligence Institute (Amii)
The Alberta Machine Intelligence Institute (Amii) is a world-leading research group at the University of Alberta in Edmonton specializing in machine intelligence. One of three hubs in Canada's Pan-Canadian AI Strategy, Amii conducts advanced research and development in the many subfields of machine learning and artificial intelligence. Amii researchers collaborate with a variety of organizations to help push the bounds of scientific knowledge and develop innovative, adaptive solutions for businesses in Alberta and beyond. Learn more at www.amii.ca

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website: http://thecse.com/

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370 0779
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.